28
Journal reading Practice Guidelines for Perioperative Blood Management American Society of Anesthesiologists Task Force on Perioperative Blood Management Anesthesiology V 122 • No 2, Feb., 2015 Present by R1 蘇蘇蘇 Instructor : Dr. 蘇蘇蘇

Journal reading

Embed Size (px)

Citation preview

Page 1: Journal reading

Journal reading

Practice Guidelines for Perioperative Blood ManagementAmerican Society of AnesthesiologistsTask Force on Perioperative Blood Management Anesthesiology V 122 • No 2, Feb., 2015

Present by R1蘇府蔚Instructor : Dr.王審之

Page 2: Journal reading

Introduction

• Guideline to improve perioperative management – Blood transfusion– Adjuvant therapies.– Reduce adverse outcomes of transfusions,

bleeding, or anemia.• To Update guideline published in 2006– Exclude neonates, infants, <35kg children, patients

not undergoing procedures.

Page 3: Journal reading

Outline of Guidelines

• I. Patient evaluation• II. Preadmission preparation• III. Preprocedure preparation• IV.

Intraoperative and postoperative management

Page 4: Journal reading

I. Patient evaluation

1. Review previous medical recordsa) Congenital / acquired diseases ; history of

transfusion reaction.b) E.g. sickle-cell, clotting factor def., hemophilia,

liver disease, hx of thrombotic events

2. Conducting interviewa) Inform risk and benefits of transfusion

3. Review existing laboratory test result4. Order additional lab tests

Page 5: Journal reading

Risk of transfusion

• Prolonged hospital stay– Infection– Transfusion-related organ damage– Transmission of pathogen–論文內好像有提到這部分,再麻煩您看看是否有遺漏

Page 6: Journal reading

II. Preadmission preparation

1. Treatment of anemia ?2. Discontinuation of anticoagulants and

antiplatelet ?3. Preadmission autologous blood donation

Page 7: Journal reading

II.-1. Treatment of anemia

• WHO definition : (g/dl)– 6m-5 y/o : 11 ; 5-12 y/o : 11.5 ; 12-15 y/o : 12– >15 y/o Non-preg. Women : 12 ; Pregnant women :

11g/dl– >15 y/o Men : 13 g/dl

• Treatment : EPO / iron supplement– EPO +/- iron vs. placebo: ↓vol. of trans.(LoE: A1-B)– EPO+ iron vs. EPO alone: insufficient evidence– Iron vs. placebo : equivocal on Hgb level/ vol.

transfusion. (LoE : A2-E)

Page 8: Journal reading

II.- 2. Discontinuation of anticoagulants and antiplatelet ?

• Stop warfarin LMWH vs. pt. no warfarin : – One observational study : equivocal (LoE: B1-E)

• Stop aspirin vs. continue use : – insufficient evidence

• + Aspirin before op. vs. placebo : equivocal– No difference on peri-op. blood loss, transfusion,

MI, major bleeding (LoE : A2-E, 2 RCTs)

Page 9: Journal reading

II. Preadmission preparation

1. Treatment of anemia ?a) CKD, Anemia of chronic disease, refusal of transfusion : EPO +/-

iron (but takes weeks, $$)b) Iron-def. anemia : iron supplement (takes time)

2. Discontinuation of anticoagulants and antiplatelet ?a) Consult specialist : stop anticoagulant (e.g. warfarin, anti-Xa) for

elective OP, shift to heparin/LMWHb) Except pt. had PCI stop non-aspirin antiplt. (e.g. clopidogrel,

ticagrelor.) sufficient time before opc) Pt. had PCI + stent : dual anti-plt. 3m for BMS, 1yr for DES

3. Preadmission autologous blood donationa) Offer the opportunity if adequate of time

Page 10: Journal reading

III. Preprocedure preparation

1. Blood management protocols2. Reversal of anticoagulants3. Antifibrinolytics for prophylaxis of excessive

blood loss4. Acute normovolemic hemodilution (ANH)

Page 11: Journal reading

III.-1. Blood management protocols

a) Multimodal protocols/algorithmsb) Restrictive vs. Liberal transfusion criteriac) Avoidance of transfusiond) Massive transfusion protocole) Maximal surgical blood order schedules

Page 12: Journal reading

III.2-Reversal of anticoagulants

a) Preprocedure administration of prothrombin complex concentrates(PCCs)– Observational study : (LoE: B4-E)

Pre-op 4-factor單位是不是有問題 ? PCC : INR↓Thromboembolic event : 0.003% of pts.

b) Administration of FFP– Insufficient study to evaluate impact.

c) Preprocedure administration of vitamin K– Immediately-pre-op Vit. K vs. placebo :

equivocal for transfusion requirement (LoE: B3-E)

Page 13: Journal reading

III.-3 Antifibrinolytics for prophylaxis of excessive blood loss

• Tranexamic acid– RCTs ( vs. placebo) no dif. in stroke, MI, AKI, mortality (LoE:

A2-B)– Meta-analyses of placebo-controlled RCTs

• Prophylaxis of excessive bleeding ( pre-op +/- intra-op)↓ pt. of transfusion & blood loss & vol. of transfusion (LoE : A1-B )

– Meta-analyses of RCTs • Prophylactic use in THA/TKA, before tourniquet deflation :↓ vol. of blood loss ( LoE : A1-B )

– One RCT : tranexamic acid in cardiac surgery• No efficacy after cardiac surgery and continue to 12H. (LoE : A3-E)

Page 14: Journal reading

III. Preprocedure preparation1. Blood management protocols

a) No single algorithm can be recommended at this timeb) Restrictive RBC transfusion protocolc) Hgb 6-10g/dl : bleeding condition, volume status, organ ischemia,

cardiopulmonary reserve

2. Reversal of anticoagulantsa) Warfarin urgent reversal : FFP / consult specialist use PCCb) Non-urgent : Vit. K.

3. Antifibrinolytics for prophylaxis of excessive blood lossa) For prophylaxis if undergoing CPBypassb) Consider use in certain Ortho op (e.g. TKA)c) Consider use in liver op / if risk of excessive bleeding

4. Acute normovolemic hemodilution (ANH)a) Major cardiac, orthopedic, thoracic, liver surgery

Page 15: Journal reading

IV. Intraoperative and postoperative management of blood loss

1. Allogeneic RBC transfusion2. Reinfusion of recovered RBC3. Intraoperative and postoperative monitoring4. Treatment of excessive bleeding

Page 16: Journal reading

IV.-2. Reinfusion of recovered RBC

• Intraoperative RBC recovery– Meta-analyses of RCTs : Effectively ↓ vol. of

allogeneic blood transfusion ( LoE : A1-B )• Postoperative RBC recovery– RCTs : Major orthopedic surgery

Effectively ↓ frequency of allogeneic blood transfusion ( LoE : A2-B )

Page 17: Journal reading

IV. -3. Intraoperative and postoperative monitoring

a) Monitoring for blood lossb) Monitoring for perfusion of vital organsc) Monitoring for anemiad) Monitoring for coagulopathye) Monitoring for adverse effects of transfusions

Page 18: Journal reading

IV.3-b. Monitoring for perfusion of vital organs

• Standard ASA monitoring.• Additional : cerebral oximetry, near infrared

spectroscopy, ABG, mixed-venous saturation.• Insufficient literature to evaluate efficacy

Page 19: Journal reading

IV.3.-d.Monitoring for coagulopathy

• Portable laser photometer as PoC test for PT/aPTT : good correlation with traditional lab, ↓ time for results ( LoE : B2-B)

• Platelet count test during CPBypass : predict excessive bleeding (Se: 83%, Sp: 58%) LoE : B2

• TEG / ROTEM : single RCT showed equivocal for transfusion requirement (???)

Page 20: Journal reading

IV.-4. Treatment of excessive bleeding

a) Transfusion of plateletsb) Transfusion of FFPc) Transfusion of cryoprecipitated) Pharmacologic treatment

① Desmopresin② Antifibrinolytics③ Topical hemostatics

e) Prothrombin complex concentratesf) Coagulation factor concerntratesg) Treatment for hypofibrinogenemia

Page 21: Journal reading

IV.4.-a. Transfusion of platelets

• Insufficient literature to evaluate of platelet transfusion on resolution of coagulopathy.

• Survey response : – obtaining platelet count / function test first.

Page 22: Journal reading

IV.4.-b. Transfusion of FFP

• ? Blood loss / ? RBC transfused / FFP ? No FFP ? – RCTs inconsistent findings

• Survey response : – obtain coagulation test before FFP transfusion

Page 23: Journal reading

IV.4.-c. Transfusion of cryoprecipitate

• Intra-op/ post-op. cryoprecipitate to manage coagulopathy : Insufficient literature

• Survey : – fibrinogen level test when excessive bleeding

before cryo. transfusion.

Page 24: Journal reading

IV. Intraoperative and postoperative management of blood loss

1. Allogeneic RBC transfusiona) Without considering blood storage duration : okb) Leukocyte-reduced: for purpose to↓complication

2. Reinfusion of recovered RBC : intraoperative blood-sparing intervention3. Intraoperatve and postoperative monitoring

a) Visual assessment (drains, suction, sponge) / Vital organs ( standard monitors + PE)

b) May use add. monitor (TEE, Br.oximetry, U/O, ABG, ScvO2)c) If suspect anemia : check EBL/PEd) If suspect coagulopathy : check INR, aPTT, fibrinogen, or TEG/ROTEM, plt count.

4. Treatment of excessive bleedinga) Check plt, plt function, PT/INR, aPTT, fibrinogen before transfusionb) Desmopressin may be use when excessive bleeding and plt dysfunction.c) Consider topical hemostatics , antifibrinolytics, fibrinogen concentrated) PCC may be used with excessive bleeding and INR ↑e) If treatment options exhausted, consider recombinant act. Factor VII.

Page 25: Journal reading

Difference from current practice

• Emphasis of preop. pts/risks assessment • Use of adjunct medication– Erythropoietin for anemia– PCC for urgent warfarin reversal– Anifibrinolytics for cardiac/high bleeding risk op.

• Advocate the use of transfusion algorithms– Real-time monitoring– Blood ordering schedules– Restrictive transfusion strategies

Page 26: Journal reading

個人心得• 需要各部門之間整合並有共識• 文章中多處使用籠統與含蓄用語• 考量現實可用之資源,發展新進技術• 可配合輔助藥物減少輸血

Page 27: Journal reading

Further question/discussion

• Choice of intraoperative lab tests / Monitoring tool ? Target of INR/HgB ?– TEG/ROTEM as monitor tool vs. TEG/ROTEM-based

algorithm : different evidence.– Vital organ monitoring

• Preoperative routine tests for patients with risks of excessive bleeding ?

• Intraoperative use of laser photometry for INR/APTT ? Check fibrinogen/plt (not only ABG?)

• VGHTPE transfusion algorithm ?

Page 28: Journal reading

THANK YOU FOR YOUR ATTENTION